NCT07054684PHASE1Recruiting

Study of BHV-1400 in IgA Nephropathy

Biohaven Therapeutics Ltd.

Start Date

7/30/2025

Completion Date

7/1/2027

Summary

The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).

Eligibility Criteria

Age Range: 18 years to 65 years

Key Inclusion Criteria: 1\. Participants must have biopsy-confirmed IgA Nephropathy Key Exclusion Criteria: 1. Any secondary IgAN 2. Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause

Interventions

DRUG

BHV-1400

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

IgA Nephropathy

Locations

Site-001

Farmington, Connecticut 06030

United States

Site-003

Miami Lakes, Florida 33016

United States

Site-011

Miami Lakes, Florida 33172

United States

Site-013

Orlando, Florida 32806

United States

Site-005

Pembroke Pines, Florida 33029

United States

Site-008

Lawrenceville, Georgia 30046

United States

Site-009

Hinsdale, Illinois 60521

United States

Site-012

Indianapolis, Indiana 46268

United States

Site-015

Shelby, Michigan 48316

United States

Site-006

Chesterfield, Missouri 63017

United States

Site-002

Dakota Dunes, South Dakota 57049

United States

Site-014

Houston, Texas 77027

United States

Site-004

Houston, Texas 77099

United States

Site-016

Salt Lake City, Utah 84115

United States

Site-007

Leicester, LE5 4PW

United Kingdom